SCHEMBL20520127

SCHEMBL20520127

O=C(O)CCOCCOCCOCCOCCNC(=O)COc1cccc(C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCCC[C@@H]2SC[C@@H]3NC(=O)N[C@@H]32)c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 3/20 0.58
PRSS2 P07478 3/20 0.58
PRSS3 P35030 3/20 0.58
TPSAB1 Q15661 3/20 0.58
PLG P00747 2/20 0.58
FOLH1 Q04609 7/20 0.57
PKM P14618 2/20 0.55
CSNK2A2 P19784 1/20 0.55
CSNK2B P67870 1/20 0.55
CSNK2A1 P68400 1/20 0.55
CAMK2B Q13554 1/20 0.55
F2 P00734 2/20 0.54
SORT1 Q99523 1/20 0.52
HSP90AB1 P08238 1/20 0.52
L3MBTL3 Q96JM7 1/20 0.51
NOXO1 Q8NFA2 1/20 0.51
LY6K Q17RY6 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20519966 1.00 PRSS1 (0.58) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL20519815 0.96 FOLH1 (0.57) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL20519968 0.93 FOLH1 (0.60) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL20520128 0.90 PRSS1 (0.56) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL18736482 0.90 GIGYF2 (0.53) FOLH1PKMSORT1
SCHEMBL18705344 0.89 CSNK2A2 (0.57) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL18736372 0.89 PRSS1 (0.55) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL20519904 0.88 FOLH1 (0.59) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL18705373 0.88 CSNK2A2 (0.58) PRSS1PRSS2PRSS3TPSAB1PLG
SCHEMBL18736240 0.88 FOLH1 (0.58) PRSS1PRSS2PRSS3TPSAB1PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 US disclosed
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2018-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 PRSS1 3209/4885PRSS2 3161/4885PRSS3 3932/4885
US-10953100-B2 Compounds and therapeutic uses thereof CD47, MYD88, NFATC1 PRSS1 3209/4885PRSS2 3161/4885PRSS3 3932/4885
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 PRSS1 3209/4885PRSS2 3161/4885PRSS3 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.